 Approximately 70 patients with HR advanced breast cancer will be enrolled. All patients will receive either fulvestrant 500 mg IM every 2 weeks x 3 then every four weeks or tamoxifen 20 mg PO daily by physician choice. Pre-menopausal women must be in chemical menopause. 